Ildstad Suzanne

DirectorTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed Jun 14, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$112K
Net Open-Market Flow
-$112K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 14, 2023Sell(S)13K$2.49$32K3.8M
Jun 13, 2023Sell(S)14K$2.56$36K3.8M
Jun 12, 2023Sell(S)17K$2.59$44K3.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 13, 2023Grant(A)21K$021K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-037183) within minutes of acceptance. Every field above traces to the original document. Verify it directly: